176 related articles for article (PubMed ID: 26647281)
1. Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.
Macatangay BJ; Riddler SA; Wheeler ND; Spindler J; Lawani M; Hong F; Buffo MJ; Whiteside TL; Kearney MF; Mellors JW; Rinaldo CR
J Infect Dis; 2016 May; 213(9):1400-9. PubMed ID: 26647281
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
3. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.
Thompson M; Heath SL; Sweeton B; Williams K; Cunningham P; Keele BF; Sen S; Palmer BE; Chomont N; Xu Y; Basu R; Hellerstein MS; Kwa S; Robinson HL
PLoS One; 2016; 11(10):e0163164. PubMed ID: 27711228
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
[TBL] [Abstract][Full Text] [Related]
5. Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals.
Thiébaut R; Hejblum BP; Hocini H; Bonnabau H; Skinner J; Montes M; Lacabaratz C; Richert L; Palucka K; Banchereau J; Lévy Y
Front Immunol; 2019; 10():874. PubMed ID: 31105698
[TBL] [Abstract][Full Text] [Related]
6. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.
Lévy Y; Thiébaut R; Montes M; Lacabaratz C; Sloan L; King B; Pérusat S; Harrod C; Cobb A; Roberts LK; Surenaud M; Boucherie C; Zurawski S; Delaugerre C; Richert L; Chêne G; Banchereau J; Palucka K
Eur J Immunol; 2014 Sep; 44(9):2802-10. PubMed ID: 25042008
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.
Niu L; Termini JM; Kanagavelu SK; Gupta S; Rolland MM; Kulkarni V; Pavlakis GN; Felber BK; Mullins JI; Fischl MA; Stone GW
Vaccine; 2011 Mar; 29(11):2110-9. PubMed ID: 21241732
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.
Macatangay BJ; Szajnik ME; Whiteside TL; Riddler SA; Rinaldo CR
PLoS One; 2010 Mar; 5(3):e9852. PubMed ID: 20352042
[TBL] [Abstract][Full Text] [Related]
11. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
Eller MA; Slike BM; Cox JH; Lesho E; Wang Z; Currier JR; Darden JM; Polonis VR; Vahey MT; Peel S; Robb ML; Michael NL; Marovich MA
PLoS One; 2011; 6(9):e24254. PubMed ID: 21949699
[TBL] [Abstract][Full Text] [Related]
12. Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
Leal L; Couto E; Sánchez-Palomino S; Climent N; Fernández I; Miralles L; Romero Y; González T; Maleno MJ; Paño B; Pich J; Nicolau C; Gatell JM; Plana M; García F;
Front Immunol; 2021; 12():767370. PubMed ID: 34858423
[TBL] [Abstract][Full Text] [Related]
13. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.
Li JZ; Heisey A; Ahmed H; Wang H; Zheng L; Carrington M; Wrin T; Schooley RT; Lederman MM; Kuritzkes DR;
AIDS; 2014 Nov; 28(18):2649-57. PubMed ID: 25254301
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.
Sneller MC; Justement JS; Gittens KR; Petrone ME; Clarridge KE; Proschan MA; Kwan R; Shi V; Blazkova J; Refsland EW; Morris DE; Cohen KW; McElrath MJ; Xu R; Egan MA; Eldridge JH; Benko E; Kovacs C; Moir S; Chun TW; Fauci AS
Sci Transl Med; 2017 Dec; 9(419):. PubMed ID: 29212716
[TBL] [Abstract][Full Text] [Related]
15. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.
Climent N; Guerra S; García F; Rovira C; Miralles L; Gómez CE; Piqué N; Gil C; Gatell JM; Esteban M; Gallart T
PLoS One; 2011; 6(5):e19644. PubMed ID: 21625608
[TBL] [Abstract][Full Text] [Related]
17. Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.
Miller E; Spadaccia M; Sabado R; Chertova E; Bess J; Trubey CM; Holman RM; Salazar A; Lifson J; Bhardwaj N
Vaccine; 2015 Jan; 33(2):388-95. PubMed ID: 25444812
[TBL] [Abstract][Full Text] [Related]
18. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.
García F; Climent N; Guardo AC; Gil C; León A; Autran B; Lifson JD; Martínez-Picado J; Dalmau J; Clotet B; Gatell JM; Plana M; Gallart T;
Sci Transl Med; 2013 Jan; 5(166):166ra2. PubMed ID: 23283367
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.
Connolly NC; Whiteside TL; Wilson C; Kondragunta V; Rinaldo CR; Riddler SA
Clin Vaccine Immunol; 2008 Feb; 15(2):284-92. PubMed ID: 17942609
[TBL] [Abstract][Full Text] [Related]
20. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
Andrieu JM; Lu W
J Intern Med; 2007 Feb; 261(2):123-31. PubMed ID: 17241177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
